{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:48:56Z","timestamp":1790243336332,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41380-021-01254-3","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T14:03:15Z","timestamp":1628776995000},"page":"7098-7099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Repurposing antidepressants inhibiting the sphingomyelinase acid\/ceramide system against COVID-19: current evidence and potential mechanisms"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-1349","authenticated-orcid":false,"given":"Nicolas","family":"Hoertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-8641","authenticated-orcid":false,"given":"Marina","family":"S\u00e1nchez-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Cougoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Gulbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-3987","authenticated-orcid":false,"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carpinteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin Anne","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-4590","authenticated-orcid":false,"given":"Angela M.","family":"Reiersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-4721","authenticated-orcid":false,"given":"C\u00e9dric","family":"Lemogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Limosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"1254_CR1","doi-asserted-by":"publisher","unstructured":"Salles J, Briand-M\u00e9sange F, Trudel S, Ausseil J, Salles J-P, Chap H. Can antidepressants unlock prescription of rimonabant in the fight against COVID-19? Mol Psychiatry. 2021:1\u20132. https:\/\/doi.org\/10.1038\/s41380-021-01221-y. Epub ahead of print.","DOI":"10.1038\/s41380-021-01221-y"},{"key":"1254_CR2","doi-asserted-by":"publisher","unstructured":"Stip E, Arnone D, Abdel Aziz K, Javaid S. Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties. Mol Psychiatry. 2021:1\u20135. https:\/\/doi.org\/10.1038\/s41380-021-01222-x. Epub ahead of print.","DOI":"10.1038\/s41380-021-01222-x"},{"key":"1254_CR3","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021. https:\/\/doi.org\/10.1038\/s41380-021-01021-4 Epub ahead of print.","DOI":"10.1038\/s41380-021-01021-4"},{"key":"1254_CR4","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. SSRIs and SNRIs and Risk of Death or Intubation in COVID-19: Results from an Observational Study. medRxiv 2020.07.09.20143339; https:\/\/doi.org\/10.1101\/2020.07.09.20143339.","DOI":"10.1101\/2020.07.09.20143339"},{"key":"1254_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000315101","volume":"26","author":"J Kornhuber","year":"2010","unstructured":"Kornhuber J, Tripal P, Reichel M, M\u00fchle C, Rhein C, Muehlbacher M, et al. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26:9\u201320.","journal-title":"Cell Physiol Biochem"},{"key":"1254_CR6","doi-asserted-by":"publisher","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100142. Epub 2020 Oct 29.","DOI":"10.1016\/j.xcrm.2020.100142"},{"key":"1254_CR7","doi-asserted-by":"publisher","unstructured":"Carpinteiro A, Gripp B, Hoffmann M, P\u00f6hlmann S, Hoertel N, Edwards MJ, et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;296:100701. https:\/\/doi.org\/10.1016\/j.jbc.2021.100701. Epub 2021 Apr 23.","DOI":"10.1016\/j.jbc.2021.100701"},{"key":"1254_CR8","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","volume":"9","author":"S Schloer","year":"2020","unstructured":"Schloer S, Brunotte L, Goretzko J, Mecate-Zambrano A, Korthals N, Gerke V, et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9:2245\u201355.","journal-title":"Emerg Microbes Infect"},{"key":"1254_CR9","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez\u2010Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID\u201019: an observational multicenter study. Clin Pharmacol Ther. 2021:10.1002\/cpt.2317. https:\/\/doi.org\/10.1002\/cpt.2317. Epub ahead of print.","DOI":"10.1002\/cpt.2317"},{"key":"1254_CR10","doi-asserted-by":"publisher","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Abell\u00e1n M, et al. Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: an Observational Study. medRxiv 2021.02.18.21251997; https:\/\/doi.org\/10.1101\/2021.02.18.21251997.","DOI":"10.1101\/2021.02.18.21251997"},{"key":"1254_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ph14030226","volume":"14","author":"G Darquennes","year":"2021","unstructured":"Darquennes G, Le Corre P, Le Moine O, Loas G. Association between functional inhibitors of acid sphingomyelinase (Fiasmas) and reduced risk of death in covid-19 patients: a retrospective cohort study. Pharmaceuticals. 2021;14:226.","journal-title":"Pharmaceuticals."},{"key":"1254_CR12","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: a Randomized Clinical Trial. JAMA. 2020;324:2292\u20132300.","journal-title":"JAMA."},{"key":"1254_CR13","doi-asserted-by":"publisher","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","volume":"8","author":"D Seftel","year":"2021","unstructured":"Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum Infect Dis. 2021;8:ofab050.","journal-title":"Open Forum Infect Dis"},{"key":"1254_CR14","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.3390\/ijms22094794","volume":"22","author":"J Mar\u00edn-Corral","year":"2021","unstructured":"Mar\u00edn-Corral J, Rodr\u00edguez-Morat\u00f3 J, Gomez-Gomez A, Pascual-Guardia S, Mu\u00f1oz-Berm\u00fadez R, Salazar-Degracia A, et al. Metabolic Signatures Associated with Severity in Hospitalized COVID-19 Patients. Int J Mol Sci. 2021;22:4794.","journal-title":"Int J Mol Sci"},{"key":"1254_CR15","doi-asserted-by":"publisher","unstructured":"Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et al. Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro. bioRxiv 2021.03.22.436379; https:\/\/doi.org\/10.1101\/2021.03.22.436379.","DOI":"10.1101\/2021.03.22.436379"},{"key":"1254_CR16","doi-asserted-by":"publisher","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"VP Sukhatme","year":"2021","unstructured":"Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a Review of Its Mechanism of Action and Its Role in COVID-19. Front Pharm. 2021;12:652688.","journal-title":"Front Pharm"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01254-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T06:59:52Z","timestamp":1645685992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01254-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01254-3","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NH, MS-R, EG, JK, AC, and FL are inventors on a patent application related to methods of treating COVID-19, filled by Assistance Publique \u2014Hopitaux de Paris in France. NH has received personal fees and nonfinancial support from Lundbeck, outside the submitted work. AMR and EJL are inventors on a patent application related to methods of treating COVID-19, which was filed by Washington University in St. Louis. EJL has received consulting fees from Johnson and Johnson, and Jazz Pharmaceuticals. AMR has received grant or research support from the McDonnell Center for Systems Neuroscience, the McDonnell Center for Cellular and Molecular Neurobiology, and the Taylor Family Institute for Innovative Psychiatric Research. DS is the Chief Medical Officer and CEO of Enable Biosciences, a CLIA certified Federal clinical reference laboratory that performs COVID-19 antibody testing. CL reports personal fees and nonfinancial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Euth\u00e9rapie-Servier, and Lundbeck, outside the submitted work. Other authors declare no competing interests related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}